Raje, N
Vadhan-Raj, S
Willenbacher, W
Terpos, E
Hungria, V
Spencer, A
Alexeeva, Y
Facon, T
Stewart, A K
Feng, A
Braun, A
Balakumaran, A
Roodman, G D
Article History
Received: 14 April 2015
Revised: 18 August 2015
Accepted: 2 September 2015
First Online: 8 January 2016
Competing interests
: N Raje has received honoraria from Celgene, Millennium and Onyx for advisory boards and research funding from Eli Lilly, Actelion and Amgen. W Willenbacher has received honoraria from Amgen for educational lectures, data acquisition in noninterventional studies and participation in advisory boards, as well as research grants and is a member of the steering committee of the AMGEN 20090482 trial. S Vadhan-Raj has received honoraria from Amgen for participation in the advisory board, and research funding for clinical trials. E Terpos has received honoraria from Amgen for participation in advisory boards and also research grants; he is a member of the steering committee of the Amgen 20090482 trial. GD Roodman has received consultancy fees from Amgen. T Facon has received advisory board fees from Amgen and Novartis. A Balakumaran and A Feng are employees of Amgen and hold Amgen stock. A Braun was an employee of Amgen when the work was conducted. AK Stewart, V Hungria, A Spencer and Y Alexeeva declare no conflict of interest.